EDG-5506 is an oral small molecule muscle stabilizer. EDG-5506 seeks to protect the muscle from injuries due to hypercontractal stress when dystrophin is absent or has reduced function. By helping to shield the muscle from damage and limit the muscle breakdown EDG-5506 may provide benefit to individuals living with Duchenne and Becker.
EDG-5506 is currently being evaluated for safety in a Phase 1 trial with healthy control and Becker patients.
This program is sponsored by Edgewise Therapeutics.
JUNE 2021 | Edgewise Therapeutics at the PPMD 2021 Virtual Annual ConferencePre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library |
